Compounded Medication – Prescription Only

This product is a compounded injectable formulation containing ARA-290 (also known as cibinetide) supplied in a sterile injectable vial and dispensed only pursuant to a valid prescription issued by a licensed healthcare provider.

In compounding practice, peptide formulations may be prescribed when a provider determines that individualized formulation or concentration considerations are clinically appropriate for a specific patient. This product is not available for self-selection and may only be dispensed following provider authorization.

Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). The FDA does not evaluate compounded formulations for safety, effectiveness, or quality. Compounding is performed by a state-licensed pharmacy pursuant to a patient-specific prescription.

This page provides general, non-therapeutic information for educational and compliance purposes only. It does not describe intended use, therapeutic benefit, physiologic effect, or expected clinical outcomes.

General Scientific Information (Non-Therapeutic)

ARA-290, also referred to as cibinetide, is a synthetic peptide derived from a truncated region of the erythropoietin (EPO) molecule. Scientific literature references its molecular structure and biochemical characteristics, including receptor-binding properties studied in laboratory and research environments.

Descriptions of molecular characteristics or biochemical properties are provided solely for general scientific context. No claims are made regarding safety, effectiveness, mechanisms of action, clinical outcomes, or suitability for any particular condition.

Contraindications

ARA-290 injection should not be used in individuals who have a known hypersensitivity or allergy to ARA-290, peptide-based compounds, or any component of the compounded formulation, have experienced prior adverse reactions to injectable peptide preparations, or are unable to tolerate injectable therapies as determined by the prescribing healthcare provider.

Use in pregnant or breastfeeding individuals should occur only if a licensed healthcare provider determines that potential risks and benefits have been carefully evaluated.

Warnings and Precautions

Peptide-based injectable formulations may elicit hypersensitivity reactions in some individuals. Patients should be monitored for signs of allergic response following administration.

Injectable administration should be performed only as prescribed and supervised by a licensed medical provider.

Patients should inform their healthcare provider of all medical conditions, allergies, and medications prior to receiving this compounded formulation.

Potential Side Effects

Reported side effects associated with injectable peptide formulations may include injection site reactions such as pain, redness, swelling, or irritation; headache; dizziness or lightheadedness; nausea; or fatigue.

Serious adverse reactions are uncommon but may occur. Patients should seek immediate medical attention if they experience signs of an allergic reaction, including difficulty breathing, swelling of the face or throat, or severe rash.